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The double-edged sword - prosthetic
joint infection following BCG treatment
for bladder cancer: a case report
Minh-Vu Hoang Nguyen1, Mauro M. Giordani2 and George R. Thompson III3,4*
Abstract
Background: Prosthetic joint infections remain a significant cause of morbidity and are frustrating for patients and
physicians alike. Unusual causes of infection may be seen in selected circumstances and a high index of suspicion
and a careful history are required to ensure an accurate and timely diagnosis can be made.
Case presentation: We present a case of Mycobacterium bovis prosthetic joint infection secondary to intravesicular
Bacillus Calmette-Guérin (BCG) treatment for prior bladder cancer definitively identified by spoligotyping. A favorable
clinical outcome was observed following surgical intervention and a 12-month course of anti-mycobacterial therapy.
Conclusions: BCG therapy, a live attenuated strain of M. bovis, has become the mainstay of adjunctive therapy for
bladder cancer and infectious complications, including those affecting the musculoskeletal system, may be seen years
after initial therapy. An awareness of this complication and appropriate discussions with the institution’s microbiology
laboratory may allow for an accurate and timely identification.
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Background
Prosthetic joint infections remain a significant problem
and affect 1–2% of all joint replacement surgeries [1].
The majority of these infections are caused by bacterial
pathogens such as Staphylococcus aureus, gram-negative
bacilli, or from mixed infections [2]. The diagnosis of
less-common causes of infection requires a careful
history and thoughtful discussions with the microbiology
laboratory to ensure other potential etiologic agents can
be sought and thereafter definitively identified.
Case presentation
A 90-year-old Hispanic male dairy farmer with a complex
medical history notable for a left total hip arthroplasty
(THA), bladder carcinoma in situ status-post intravesicu-
lar Bacillus Calmette-Guérin (BCG) (a live attenuated
strain of Mycobacterium bovis) treatment, and chronic
kidney disease who presented with subacute worsening
pain of his left thigh. He had a THA placed thirty-one
years previously. He had papillary bladder tumor
status-post fulguration five years prior to admission with
subsequent recurrence of bladder carcinoma in situ
diagnosed a year later; he underwent six initial and six
maintenance instillations of BCG treatment with re-
mission of his bladder cancer.
Four years after BCG therapy, the patient developed
new-onset drainage from the left lateral thigh. This was
followed by swelling of his entire left thigh with increasing
purulent discharge and pain with movement. He sub-
sequently experienced chills, rigors, and a fever of 101 °F
the morning prior to admission. On presentation he was
afebrile with normal vital signs. His exam was significant
for an open wound on the lateral left thigh with purulent
drainage and surrounding erythema. Pain was noted
adduction of the left hip. Initial laboratory tests were
notable for a white blood cell count of 10,200 cells/mm3, a
C-reactive protein of 9.7 mg/dL, and sedimentation rate of
71mm/hr. Radiograph of the left hip showed “extensive
lucencies” around the left THA (Fig. 1).
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The patient underwent incision and drainage with an
antibiotic spacer placed following admission. Wound,
hip fluid, and abscess cultures obtained during irrigation
and debridement were negative for bacterial pathogens,
however given his history of prior BCG therapy the
microbiology laboratory was asked to additionally per-
form mycobacterial cultures and these grew acid-fast
bacilli (AFB) concerning for Mycobacterium tuberculosis
complex. After a brief course of clindamycin, ceftria-
xone, vancomycin, and metronidazole, he was started on
isoniazid 300mg PO daily, rifampin 600 mg PO daily,
pyrazinamide 1500 mg daily, ethambutol 1200 mg daily,
and Vitamin B6 50 mg PO daily. He was placed in
temporary airborne isolation while he had three sputa
assessed for active pulmonary tuberculosis, which were
negative for Mycobacterium spp. Nucleic Acid Amplifi-
cation Testing (Cepheid, Sunnyvale, California) detected
Mtb complex in his hip fluid culture.
Susceptibility testing for Mtb complex showed monore-
sistance to pyrazinamide, which was suggestive of M. bovis.
As the patient had prior exposure to livestock and BCG
therapy the isolate was further evaluated by spacer
oligonucleotide typing (spoligotyping) and found by the
California State Department of Health to be identical to
that of the vaccine strain M. bovis BCG used previously
in the treatment of his bladder cancer. The patient
completed a 12 month course of rifampin, isoniazid and
ethambutol without event and free of symptomatic, or
radiographic recurrence.
Discussion and conclusions
Our case illustrates an M. bovis prosthetic joint infection
as a complication of intravesicular BCG therapy. M.
bovis is a zoonotic mycobacteria related to Mtb known
to cause tuberculosis in cattle, also known as bovine
tuberculosis, and other animals. It is recently better
known for its employment in modern medicine as the
primary ingredient in the BCG vaccine that protects
humans from Mtb infection and the intravesicular BCG
therapy for bladder carcinoma. Despite our ability to
harness this organism for potential therapeutic benefit,
[3] it still retains its ability to cause human disease.
M. bovis infects humans by either transmission from an
infected animal or M. bovis-derived therapeutic interven-
tion (BCG). Direct exposure to M. bovis-infected animals
can lead to tuberculosis in humans; immunocompromised
individuals are the most susceptible, notably those with
human immunodeficiency virus co-infection [4]. Other risk
factors pertinent to our case are Hispanic descent and
other immunosuppressed states including chronic kidney
disease [5]. Among those who are exposed to cattle a com-
mon route of transmission is ingestion of unpasteurized
milk from an infected cow, but because of the advent of
farming infection control and milk pasteurization, this has
become less common [6]. Our patient was infected by his
BCG therapy for his bladder carcinoma, which was con-
firmed by spoligotyping to differentiate from any potential
M. bovis exposure he may have previously encountered as
a dairy farmer.
A wide range of BCG infections as complications from
prior therapy for bladder carcinoma have been described
[7–11]. Prosthetic joint infections are exceedingly rare,
with few cases previously presented and none confirmed
by spoligotyping/PCR as BCG [12–20]. The nine cases
reviewed consist of middle-to-elderly age patients, eight
of which were men, without specified ethnicity who had
joint arthroplasties and bladder carcinoma needing
instillations of BCG therapy. They generally present
months to years after their last BCG instillation with
worsening localized pain at the site of their arthroplas-
ties and evidence of local bone lesions on radiograph
[12, 14–20]. Only one case had a co-morbid immu-
nosuppressive diagnosis (diabetes) [14], only one had
systemic B-symptoms [18], and five had elevated serum
measurements of acute phase reactants [13, 15–18]. All
cases had microbiological confirmation of M. bovis and
received appropriate anti-tuberculous treatment in
addition to surgical source control. Our case is different
than the prior cases as he is the first to have PCR con-
firmed BCG infection rather than probable infection
with BCG (the presence of M. bovis in a patient with
prior BCG).
Identifying an M. bovis infection is both clinically, radio-
graphically, and microbiologically challenging because it is
Fig. 1 Peri-prosthetic lucency consistent with long-standing infection
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part of the Mtb complex with Mycobacterium tuberculosis,
Mycobacterium africanum, and Mycobacterium microti
[21]. Clinicians diagnose M. bovis in a similar approach to
an Mtb infection. Radiographic findings can be non-spe-
cific and mimic malignancy, or other infectious causes ne-
cessitating a tissue diagnosis for confirmation [22]. initially
with microscopy with AFB staining followed by culture
and nucleic acid testing of pertinent specimens. Because
M. bovis is innately resistant to pyrazinamide, it is often
suggested based on monoresistance to pyrazinamide on
susceptibility testing; more advanced molecular genetic
testing is required for definitive diagnosis [23]. For this
case, spoligotyping was employed to identify and confirm
the etiology as BCG [24]. In addition to surgical source
control needed for a prosthetic joint infection, treatment
for BCG and other mycobacterial infections consists of
rifampin, isoniazid, and ethambutol for 12months [25, 26].
In summary, our case is an elderly man with con-
firmed BCG prosthetic joint infection from his prior
intravesicular BCG therapy. Such complications are
exceedingly rare and reinforce the need for a thorough
history and a high index of suspicion to make an accu-
rate diagnosis. Clinicians should suspect this infection in
elderly or immunocompromised patients with an in-
fected prosthesis and a history of intravesicular BCG
therapy. If a mycobacterial culture grows Mtb complex
with monoresistance to pyrazinamide, clinicians can
consider spoligotyping to definitively diagnose BCG and
trace the strain to its source.
Prosthetic joint infection from the BCG strain of
M. bovis is a rare infectious complication of prior BCG
therapy and requires a high-index of suspicion. A thorough
history and working knowledge of unusual causes of
prosthetic joint infection allowed for a rapid diagnosis
and initiation of therapy.
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